MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$32,146K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from maturities of inve...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchase of investments
Non-cash collaboration revenue -...
Operating lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue - related party
4,640
-
-
0
Total operating expenses
51,560
-120,819
-
166,911
Other income (expenses), net
4,243
-11,350
-
14,835
Net loss
-42,677
-42,607
-38,810
-41,400
Stock-based compensation
12,440
8,270
8,130
8,652
Depreciation and amortization
2,645
2,869
3,057
3,097
Net amortization/accretion on investment securities
1,313
885
821
923
Impairment of long-lived assets
0
-
0
0
Impairment of equity investment and equity method investment
-
-
0
-
Non-cash rent expense
1,080
1,069
1,047
1,031
Tax benefit at federal statutory rate
-
-
-40,086
-
Research tax credits
-
-
1,783
-
Change in valuation allowance
-
-
35,414
-
Stock-based compensation
-
-
6,280
-
Other
-
-
175
-
Other adjustments
-
-
0
-
Income tax expense
-
-
0
-
Non-cash collaboration revenue - related party
4,640
-
0
0
Share of loss from equity method investments
-
-
0
0
Deposit placed in escrow
0
-23,479
7
-12
Prepaid expenses and other current assets
989
-1,132
-986
-1,010
Other long-term assets
166
-84
102
-315
Accounts payable
1,031
663
599
-1,072
Accrued and other current liabilities
2,280
-5,101
-118
1,086
Operating lease liabilities
-2,043
-2,202
-1,889
-1,855
Other long-term liabilities
356
316
329
359
Net cash used in operating activities
-31,996
-12,913
-27,599
-29,688
Purchases of property and equipment
150
9
0
243
Proceeds from sales of investments
-
-
0
0
Proceeds from maturities of investments
36,312
72,115
61,990
61,912
Purchase of investments
183,721
101,694
28,377
49,734
Net cash provided by (used in) investing activities
-147,559
-29,588
33,613
11,935
Proceeds from issuance of common stock from public offering, net of commissions and issuance costs-ATMOffering
0
20,668
7,859
2,979
Proceeds from issuance of common stock from public offering, net of commissions and issuance costs-Public Offering
187,872
-
0
0
Proceeds from cirm award (note 5)
0
0
0
0
Proceeds from issuance of common stock upon exercise of stock options
0
4
0
0
Proceeds from issuance of common stock under the employee stock purchase plan
0
450
0
257
Net cash provided by financing activities
187,872
21,122
7,859
3,236
Net change in cash and cash equivalents and restricted cash
8,317
-21,379
13,873
-14,517
Cash and cash equivalents and restricted cash beginning of period
40,601
61,980
48,107
85,510
Cash and cash equivalents and restricted cash end of period
48,918
40,601
61,980
48,107
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock from...
$187,872K
Net cash provided by
financing activities
$187,872K
(885.58%↑ Y/Y)
Net change in cash
and cash...
$8,317K
(136.34%↑ Y/Y)
Canceled cashflow
$179,555K
Proceeds from maturities
of investments
$36,312K
(-67.08%↓ Y/Y)
Stock-based compensation
$12,440K
(-40.36%↓ Y/Y)
Depreciation and
amortization
$2,645K
(-57.37%↓ Y/Y)
Accrued and other
current liabilities
$2,280K
(165.37%↑ Y/Y)
Non-cash rent expense
$1,080K
(-52.57%↓ Y/Y)
Accounts payable
$1,031K
(236.02%↑ Y/Y)
Other long-term
liabilities
$356K
(-20.36%↓ Y/Y)
Net cash provided by
(used in) investing...
-$147,559K
(-395.05%↓ Y/Y)
Net cash used in
operating activities
-$31,996K
(65.21%↑ Y/Y)
Canceled cashflow
$36,312K
Canceled cashflow
$19,832K
Collaboration revenue -
related party
$4,640K
Other income
(expenses), net
$4,243K
Purchase of investments
$183,721K
(205.46%↑ Y/Y)
Net loss
-$42,677K
(61.44%↑ Y/Y)
Purchases of property and
equipment
$150K
(4.90%↑ Y/Y)
Canceled cashflow
$8,883K
Non-cash collaboration
revenue - related party
$4,640K
Operating lease
liabilities
-$2,043K
(45.65%↑ Y/Y)
Net
amortization/accretion on investment...
$1,313K
(-46.99%↓ Y/Y)
Prepaid expenses and
other current assets
$989K
(179.63%↑ Y/Y)
Other long-term
assets
$166K
(-88.96%↓ Y/Y)
Total operating
expenses
$51,560K
Buy us a coffee
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)